%0 Journal Article
%T Treatment approaches in autoimmune pancreatitis (Review).
%A Pădureanu V
%A Drăgoescu AN
%A Pădureanu R
%A Rośu MM
%A Rădulescu D
%A Dop D
%A For Ofoiu MC
%J Biomed Rep
%V 20
%N 2
%D 2024 Feb
%M 38259589
暂无%R 10.3892/br.2023.1714
%X Autoimmune pancreatitis (AIP) is a rare disease. There are two distinct types of AIP: AIP type 1 (AIP-1), a pancreatic manifestation of a multi-organ disease linked to immunoglobulin (Ig)G4, and AIP type 2 (AIP-2), a pancreas-specific disease unrelated to IgG4. The usual course of treatment for AIP is oral corticosteroid medication. Rituximab has also been recommended for recurrent AIP-1 in order to initiate remission and provide ongoing treatment. Immunomodulators such as azathioprine are used to keep certain patients in remission. Evaluation also takes into account a number of pharmacological alternatives, including biologic drugs like anti-tumor necrosis factor therapy, a safe and efficient second-line treatment for AIP-2 relapse or steroid dependence. Corticosteroids and immunosuppressants, which are poorly tolerated due to considerable side effects, are being replaced by other biologic drugs, which may offer a beneficial therapeutic alternative.